Stromal Therapeutics develops cell-based therapies utilizing stromal cells to promote tissue regeneration in patients with degenerative diseases. Their technology targets the limitations of current regenerative medicine treatments by enhancing the body's natural repair mechanisms.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for inflammatory heart disease lack specificity, often failing to address the underlying causes of tissue inflammation and cytokine dysregulation. This results in limited efficacy and potential side effects for patients.
Solution
Stromal Therapeutics is developing immunotherapies that target tissue cytokines and their inhibitors produced by stromal cells to treat inflammatory diseases. Their approach focuses on modulating the tissue stroma to regulate inflammation at the source. Their lead compound has demonstrated efficacy in preclinical models of inflammatory heart disease, an indication with no specific therapy. By targeting locally acting, drugable targets in chronic diseases, Stromal Therapeutics aims to provide more effective and targeted treatments.
Target Audience
The primary target audience includes patients suffering from inflammatory heart disease and other chronic inflammatory conditions, as well as the clinicians treating these diseases.
Features
- New generation immunotherapies targeting tissue cytokines and their inhibitors
- Focus on molecules regulated at sites of inflammation
- Lead compound demonstrating efficacy in preclinical models of inflammatory heart disease